Holen Sie sich die Stockscreener-App
158.21
1.42%
2.208
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$156.00
Offen:
$157.17
24-Stunden-Volumen:
1.15M
Relative Volume:
0.96
Marktkapitalisierung:
$22.77B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.62B
KGV:
8.6123
EPS:
18.37
Netto-Cashflow:
$1.77B
1W Leistung:
-4.05%
1M Leistung:
-14.32%
6M Leistung:
-30.52%
1J Leistung:
-31.08%
1-Tages-Spanne:
$154.74
$159.10
1-Wochen-Bereich:
$153.62
$166.34
52-Wochen-Spanne:
$153.62
$268.30
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BIIB | 158.16 | 22.77B | 9.61B | 1.62B | 1.77B | 18.37 |
| LLY | 750.85 | 703.88B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 102.84 | 467.74B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 155.60 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 171.98 | 296.46B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 99.30 | 248.23B | 63.17B | 12.15B | 14.84B | 1.80 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen (NASDAQ:BIIB) Given New $207.00 Price Target at Mizuho - MarketBeat
Primecap Management Co. CA Sells 23,215 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Unusual Options Activity For November 20 - Benzinga
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - Yahoo Finance
ANCA Vasculitis Pipeline Trends 2024: Clinical Trials, - openPR
Biogen ‘welcomes’ EC decision to revoke CMAs for generic versions of Tecfidera - MSN
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More - BioSpace
(BIIB) Pivots Trading Plans and Risk Controls - Stock Traders Daily
European committee takes a second look at Alzheimer's drug and now says it should be approved - MSN
Biogen at the 7th Annual Evercore HealthCONx Conference - Biogen | Investor Relations
Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Biogen to Participate in the 7th Annual Evercore HealthCONx Conference - Biogen | Investor Relations
Biogen, UCB release phase 3 data on lupus candidate dapirolizumab - MSN
Biogen, UCB Reveal Details Behind Surprise Late-Stage Win in Lupus, Eyes Second Phase III - BioSpace
Biogen/Eisai’s Alzheimer’s drug lecanemab receives CHMP recommendation - PMLiVE
Thrivent Financial for Lutherans Reduces Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
UCB: positive phase 3 results in lupus - Marketscreener.com
Empowered Funds LLC Has $3.67 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen: positive phase 3 results in lupus - Marketscreener.com
BIIBBiogen Inc. Latest Stock News & Market Updates - StockTitan
Biogen/UCB’s Lupus Drug Shows Consistent Efficacy Across Endpoints, Over Time - Citeline News & Insights
Dapirolizumab Pegol Phase 3 Data Presented at the American - GlobeNewswire
Biogen's Lupus Drug Shows 49.5% Response Rate in Phase 3 Trial, Beats Standard Care | BIIB Stock News - StockTitan
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 - Yahoo Finance
Needham downgrades Biogen on slow growth of Alzheimer's drug By Investing.com - Investing.com Canada
Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales (NASDAQ:BIIB) - Seeking Alpha
Needham downgrades Biogen on slow growth of Alzheimer's drug - Investing.com
Opuviz is latest EC-approved ophthalmology biosimilar - The Pharma Letter
Biogen (NASDAQ:BIIB) Sets New 12-Month LowShould You Sell? - MarketBeat
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ - Biogen | Investor Relations
Biogen (NASDAQ:BIIB) Downgraded to "Hold" Rating by Needham & Company LLC - MarketBeat
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ - GlobeNewswire
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ - GlobeNewswire Inc.
Analyst recommendations: Biogen, HP, Moderna, Shell... - Marketscreener.com
KBC Group NV Has $6.44 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now? - Insider Monkey
Top 10 Alzheimer’s Disease Therapeutics Companies | Provides Best TreatmentsMarket.us Media - Market.us Media - United States Market News
Seizert Capital Partners LLC Raises Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Mizuho Securities USA LLC Grows Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
ING Groep NV Has $3.81 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Impax Asset Management Group plc Has $7.52 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Los Angeles Capital Management LLC Purchases Shares of 4,282 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
How a Biogen drug set the stage for a new biotech targeting ALS - BioPharma Dive
BIIB (Biogen) Total Inventories : $2,469 Mil (As of Sep. 2024) - GuruFocus.com
Biogen Unusual Options Activity - Benzinga
Cornercap Investment Counsel Inc. Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe - Yahoo Finance
Biogen (NASDAQ:BIIB) Now Covered by Analysts at Wolfe Research - MarketBeat
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):